Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00476671 |
Recruitment Status
:
Completed
First Posted
: May 22, 2007
Last Update Posted
: October 21, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
HIV Infections | Procedure: lumbar puncture, MRI, MRS |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Prevalence and Risk Factors of HIV-Associated Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1 Infected Thai Individuals With Undetectable Viral Load in the HAART Era. |
Study Start Date : | March 2007 |
Actual Primary Completion Date : | April 2008 |
Actual Study Completion Date : | June 2008 |

Group/Cohort | Intervention/treatment |
---|---|
1
HIV infected adults with viral load < 50 copies/ml on NNRTI based HAART
|
Procedure: lumbar puncture, MRI, MRS
lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
|
- Neuropsychological testing score [ Time Frame: 1 day ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Signed informed consent
- Evidence of HIV infection (confirmed positive ELISA and documented history of measurable HIV RNA)
- Age > 18 years old
- Plasma HIV RNA of < 50 copies/ml within 3 months prior to screening
- Have been on only NNRTI-based HAART regimen for the entire duration and for at least1 year.
Exclusion Criteria:
- Current AIDS defining illnesses
- Current or history of previous CNS infection.
- Head injury with loss of consciousness greater than 1 hour
- Acute illness within 30 days prior to entry that, in the opinion of investigators, would prevent patients from completing the protocol required procedures.
- Known learning disability including dyslexia

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00476671
Thailand | |
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) | |
Bangkok, Thailand, 10330 |
Principal Investigator: | Jintanat Ananworanich, MD, Ph.D | The HIV Netherlands Australia Thailand Research Collaboration |
Additional Information:
Responsible Party: | Jintanat Ananworanich, HIV-NAT |
ClinicalTrials.gov Identifier: | NCT00476671 History of Changes |
Other Study ID Numbers: |
HIV-NAT 040 |
First Posted: | May 22, 2007 Key Record Dates |
Last Update Posted: | October 21, 2008 |
Last Verified: | October 2008 |
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
neuropsychiatric neurocognitive psychiatric HIV related dementia |
MCMD HIV-1 Prevalence, risk factors of neurocognitive impairment and psychiatric comorbidities in HIV-1 infected patients with undetectable viral load in the HAART era. Treatment Experienced |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |